Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Larisa I. Labzin is active.

Publication


Featured researches published by Larisa I. Labzin.


Immunity | 2014

Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation

Jia Xue; Susanne Schmidt; Jil Sander; Astrid Draffehn; Wolfgang Krebs; Inga Quester; Dominic De Nardo; Trupti D. Gohel; Martina Emde; Lisa Schmidleithner; Hariharasudan Ganesan; Andrea Nino-Castro; Michael R. Mallmann; Larisa I. Labzin; Heidi Theis; Michael Kraut; Marc Beyer; Eicke Latz; Tom C. Freeman; Thomas Ulas; Joachim L. Schultze

Summary Macrophage activation is associated with profound transcriptional reprogramming. Although much progress has been made in the understanding of macrophage activation, polarization, and function, the transcriptional programs regulating these processes remain poorly characterized. We stimulated human macrophages with diverse activation signals, acquiring a data set of 299 macrophage transcriptomes. Analysis of this data set revealed a spectrum of macrophage activation states extending the current M1 versus M2-polarization model. Network analyses identified central transcriptional regulators associated with all macrophage activation complemented by regulators related to stimulus-specific programs. Applying these transcriptional programs to human alveolar macrophages from smokers and patients with chronic obstructive pulmonary disease (COPD) revealed an unexpected loss of inflammatory signatures in COPD patients. Finally, by integrating murine data from the ImmGen project we propose a refined, activation-independent core signature for human and murine macrophages. This resource serves as a framework for future research into regulation of macrophage activation in health and disease.


Nature Immunology | 2014

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3

Dominic De Nardo; Larisa I. Labzin; Hajime Kono; Reiko Seki; Susanne Schmidt; Marc Beyer; Dakang Xu; Sebastian Zimmer; Catharina Lahrmann; Frank A. Schildberg; Johanna Vogelhuber; Michael Kraut; Thomas Ulas; Anja Kerksiek; Wolfgang Krebs; Niklas Bode; Alena Grebe; Michael L. Fitzgerald; Nicholas J. Hernandez; Bryan R. G. Williams; Percy A. Knolle; Manfred Kneilling; Martin Röcken; Dieter Lütjohann; Samuel D. Wright; Joachim L. Schultze; Eicke Latz

High-density lipoprotein (HDL) mediates reverse cholesterol transport and is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain poorly understood. Here we identify the transcriptional regulator ATF3, as an HDL-inducible target gene in macrophages that downregulates the expression of Toll-like receptor (TLR)-induced proinflammatory cytokines. The protective effects of HDL against TLR-induced inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the success of new HDL-based therapies.


Science Translational Medicine | 2016

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Sebastian Zimmer; Alena Grebe; Siril Skaret Bakke; Niklas Bode; Bente Halvorsen; Thomas Ulas; Mona Skjelland; Dominic De Nardo; Larisa I. Labzin; Anja Kerksiek; Chris Hempel; Michael T. Heneka; Victoria Hawxhurst; Michael L. Fitzgerald; Jonel Trebicka; Ingemar Björkhem; Jan Åke Gustafsson; Marit Westerterp; Alan R. Tall; Samuel D. Wright; Terje Espevik; Joachim L. Schultze; Georg Nickenig; Dieter Lütjohann; Eicke Latz

The cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin facilitates atheroprotective mechanisms through oxysterol-mediated reprogramming of macrophages. Dissolving away cholesterol Cardiovascular disease resulting from atherosclerosis is one of the most common causes of death worldwide, and additional therapies for this disease are greatly needed because not all patients can be effectively treated with existing approaches. Cyclodextrin is a common FDA-approved substance that is already used as a solubilizing agent to improve delivery of various drugs. Now, Zimmer et al. have discovered that cyclodextrin can also solubilize cholesterol, removing it from plaques, dissolving cholesterol crystals, and successfully treating atherosclerosis in a mouse model. Because cyclodextrin is already known to be safe in humans, this drug is now a potential candidate for testing in human patients for the treatment of atherosclerosis. Atherosclerosis is an inflammatory disease linked to elevated blood cholesterol concentrations. Despite ongoing advances in the prevention and treatment of atherosclerosis, cardiovascular disease remains the leading cause of death worldwide. Continuous retention of apolipoprotein B–containing lipoproteins in the subendothelial space causes a local overabundance of free cholesterol. Because cholesterol accumulation and deposition of cholesterol crystals (CCs) trigger a complex inflammatory response, we tested the efficacy of the cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin (CD), a compound that increases cholesterol solubility in preventing and reversing atherosclerosis. We showed that CD treatment of murine atherosclerosis reduced atherosclerotic plaque size and CC load and promoted plaque regression even with a continued cholesterol-rich diet. Mechanistically, CD increased oxysterol production in both macrophages and human atherosclerotic plaques and promoted liver X receptor (LXR)–mediated transcriptional reprogramming to improve cholesterol efflux and exert anti-inflammatory effects. In vivo, this CD-mediated LXR agonism was required for the antiatherosclerotic and anti-inflammatory effects of CD as well as for augmented reverse cholesterol transport. Because CD treatment in humans is safe and CD beneficially affects key mechanisms of atherogenesis, it may therefore be used clinically to prevent or treat human atherosclerosis.


Journal of Immunology | 2015

ATF3 Is a Key Regulator of Macrophage IFN Responses

Larisa I. Labzin; Susanne Schmidt; Seth L. Masters; Marc Beyer; Wolfgang Krebs; Kathrin Klee; Rainer Stahl; Dieter Lütjohann; Joachim L. Schultze; Eicke Latz; Dominic De Nardo

Cytokines and IFNs downstream of innate immune pathways are critical for mounting an appropriate immune response to microbial infection. However, the expression of these inflammatory mediators is tightly regulated, as uncontrolled production can result in tissue damage and lead to chronic inflammatory conditions and autoimmune diseases. Activating transcription factor 3 (ATF3) is an important transcriptional modulator that limits the inflammatory response by controlling the expression of a number of cytokines and chemokines. However, its role in modulating IFN responses remains poorly defined. In this study, we demonstrate that ATF3 expression in macrophages is necessary for governing basal IFN-β expression, as well as the magnitude of IFN-β cytokine production following activation of innate immune receptors. We found that ATF3 acted as a transcriptional repressor and regulated IFN-β via direct binding to a previously unidentified specific regulatory site distal to the Ifnb1 promoter. Additionally, we observed that ATF3 itself is a type I IFN–inducible gene, and that ATF3 further modulates the expression of a subset of inflammatory genes downstream of IFN signaling, suggesting it constitutes a key component of an IFN negative feedback loop. Consistent with this, macrophages deficient in Atf3 showed enhanced viral clearance in lymphocytic choriomeningitis virus and vesicular stomatitis virus infection models. Our study therefore demonstrates an important role for ATF3 in modulating IFN responses in macrophages by controlling basal and inducible levels of IFNβ, as well as the expression of genes downstream of IFN signaling.


Journal of Immunology | 2014

Cutting Edge: The UNC93B1 Tyrosine-Based Motif Regulates Trafficking and TLR Responses via Separate Mechanisms

Karin Pelka; Kshiti Phulphagar; Jana Zimmermann; Rainer Stahl; Jonathan L. Schmid-Burgk; Tobias Schmidt; Jan-Hendrik Spille; Larisa I. Labzin; Sudhir Agrawal; Ekambar R. Kandimalla; Jean-Laurent Casanova; Veit Hornung; Ann Marshak-Rothstein; Stefan Höning; Eicke Latz

Sensing of nucleic acids by TLRs is crucial in the host defense against viruses and bacteria. Unc-93 homolog B1 (UNC93B1) regulates the trafficking of nucleic acid–sensing TLRs from the endoplasmic reticulum to endolysosomes, where the TLRs encounter their respective ligands and become activated. In this article, we show that a carboxyl-terminal tyrosine-based sorting motif (YxxΦ) in UNC93B1 differentially regulates human nucleic acid–sensing TLRs in a receptor- and ligand-specific manner. Destruction of YxxΦ abolished TLR7, TLR8, and TLR9 activity toward nucleic acids in human B cells and monocytes, whereas TLR8 responses toward small molecules remained intact. YxxΦ in UNC93B1 influenced the subcellular localization of human UNC93B1 via both adapter protein complex (AP)1- and AP2-dependent trafficking pathways. However, loss of AP function was not causal for altered TLR responses, suggesting AP-independent functions of YxxΦ in UNC93B1.


Annual Review of Medicine | 2018

Innate Immunity and Neurodegeneration

Larisa I. Labzin; Michael T. Heneka; Eicke Latz

The innate immune system plays diverse roles in health and disease. It represents the first line of defense against infection and is involved in tissue repair, wound healing, and clearance of apoptotic cells and cellular debris. Excessive or nonresolving innate immune activation can lead to systemic or local inflammatory complications and cause or contribute to the development of inflammatory diseases. In the brain, microglia represent the key innate immune cells, which are involved in brain development, brain maturation, and homeostasis. Impaired microglial function, either through aberrant activation or decreased functionality, can occur during aging and during neurodegeneration, and the resulting inflammation is thought to contribute to neurodegenerative diseases. This review highlights recent advances in our understanding of the influence of innate immunity on neurodegenerative disorders such as Alzheimers disease, amyotrophic lateral sclerosis, Parkinsons disease, and Huntingtons disease.


The Journal of Allergy and Clinical Immunology | 2016

Interferons and inflammasomes: Cooperation and counterregulation in disease

Larisa I. Labzin; Mario A.R. Lauterbach; Eicke Latz

Interferons and the IL-1 family of cytokines have important roles in host defense against invading viruses and bacteria. Inflammasomes, multimeric cytosolic sensors of infection, are required for IL-1β and IL-18 processing and release. Interferons, IL-1β, and IL-18 are also implicated in autoimmune disease and chronic inflammation. Although independent but complementary pathways induce these cytokine subsets during infection, in some circumstances the cross-talk between these key inflammatory mediators is a particular requirement for effective host defense. In this review we will summarize recent discoveries concerning the potentiation of inflammasome responses by type I interferons, particularly in patients with gram-negative bacterial infections, and reflect on the molecular mechanisms of IFN-βs immunosuppressive effects through modulation of inflammasome and IL-1β signaling in patients with tuberculosisxa0and multiple sclerosis.


Nucleic Acids Research | 2014

Optimization of transcription factor binding map accuracy utilizing knockout-mouse models

Wolfgang Krebs; Susanne Schmidt; Alon Goren; Dominic De Nardo; Larisa I. Labzin; Anton Bovier; Thomas Ulas; Heidi Theis; Michael Kraut; Eicke Latz; Marc Beyer; Joachim L. Schultze

Genome-wide assessment of protein–DNA interaction by chromatin immunoprecipitation followed by massive parallel sequencing (ChIP-seq) is a key technology for studying transcription factor (TF) localization and regulation of gene expression. Signal-to-noise-ratio and signal specificity in ChIP-seq studies depend on many variables, including antibody affinity and specificity. Thus far, efforts to improve antibody reagents for ChIP-seq experiments have focused mainly on generating higher quality antibodies. Here we introduce KOIN (knockout implemented normalization) as a novel strategy to increase signal specificity and reduce noise by using TF knockout mice as a critical control for ChIP-seq data experiments. Additionally, KOIN can identify ‘hyper ChIPable regions’ as another source of false-positive signals. As the use of the KOIN algorithm reduces false-positive results and thereby prevents misinterpretation of ChIP-seq data, it should be considered as the gold standard for future ChIP-seq analyses, particularly when developing ChIP-assays with novel antibody reagents.


Archive | 2017

Inflammation in Atherosclerosis

Mario A.R. Lauterbach; Larisa I. Labzin; Eicke Latz


Cytokine | 2014

36: Modulation of innate immune responses by ATF3

Dominic De Nardo; Larisa I. Labzin; Susanne Schmidt; Seth L. Masters; Rainer Stahl; Joachim L. Schultze; Eicke Latz

Collaboration


Dive into the Larisa I. Labzin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge